ASCO: Lenvatinib Slows Resistant Thyroid Ca

CHICAGO (MedPage Today) -- The targeted agent lenvatinib extended progression-free survival among patients with treatment-refractory thyroid cancer, researchers said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1kelLbG